ArticleJMA journal2023

Exploring Predictive Risk Factors of Infusion Reactions with First Pertuzumab Administration in HER2-positive Breast Cancer Patients: A Single Institution Experience.

Kazutaka Otsuji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.